PMID- 37305431
OWN - NLM
STAT- MEDLINE
DCOM- 20230613
LR  - 20230613
IS  - 2314-6753 (Electronic)
IS  - 2314-6745 (Print)
VI  - 2023
DP  - 2023
TI  - Clinical Characteristics Associated with Adherence and Persistence in Patients 
      with Type 2 Diabetes Mellitus Treated with Dulaglutide.
PG  - 7917641
LID - 10.1155/2023/7917641 [doi]
LID - 7917641
AB  - AIMS: This study is aimed at identifying clinical characteristics associated with 
      adherence and persistence in patients with type 2 diabetes mellitus (T2DM) 
      treated with dulaglutide. MATERIALS AND METHODS: This retrospective observational 
      cohort study used the Common Data Model at Seoul National University Hospital, 
      Seoul, South Korea. Eligible subjects were followed for one year. Multivariate 
      logistic and linear regressions were used to identify the factors associated with 
      categorical (i.e., adherence status and continuation status) and continuous 
      (i.e., proportion of days covered, or PDC, and treatment duration) outcome 
      measures, respectively. Subgroup analysis was conducted involving patients at 
      high cardiovascular disease (CVD) risk (i.e., having >/=2 identifiable risk 
      factors). RESULTS: A total of 236 patients were included. Increase in age and 
      estimated glomerular filtration rate significantly increased the likelihood of 
      adherence and treatment continuation. In contrast, baseline obesity and baseline 
      use of sulfonylurea and insulin significantly reduced the likelihood of 
      continuing dulaglutide. Similarly, increase in age, switching dulaglutide dose, 
      and baseline neuropathy significantly increased PDC and treatment duration. None 
      of the adherence or persistence outcome measures were significantly different 
      between patients at high CVD risk and their matched controls. Baseline 
      hypertension and the higher baseline LDL-C level significantly increased the 
      likelihood of adherence in patients at high CVD risk. CONCLUSION: Clinical 
      characteristics of dulaglutide users that could have affected their adherence and 
      persistence were identified. Physicians treating T2DM patients with dulaglutide 
      can refer to those clinical characteristics identified in this study to optimize 
      the adherence and persistence to dulaglutide.
CI  - Copyright (c) 2023 David Seung U. Lee and Howard Lee.
FAU - Lee, David Seung U
AU  - Lee DSU
AUID- ORCID: 0000-0001-5710-1759
AD  - Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School 
      of Convergence Science and Technology, Seoul National University, Seoul 08826, 
      Republic of Korea.
AD  - Center for Convergence Approaches in Drug Development, Graduate School of 
      Convergence Science and Technology, Seoul National University, Seoul 08826, 
      Republic of Korea.
FAU - Lee, Howard
AU  - Lee H
AUID- ORCID: 0000-0001-6713-5418
AD  - Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School 
      of Convergence Science and Technology, Seoul National University, Seoul 08826, 
      Republic of Korea.
AD  - Center for Convergence Approaches in Drug Development, Graduate School of 
      Convergence Science and Technology, Seoul National University, Seoul 08826, 
      Republic of Korea.
AD  - Department of Clinical Pharmacology and Therapeutics, Seoul National University 
      College of Medicine and Hospital, Seoul 03080, Republic of Korea.
AD  - Advanced Institute of Convergence Technology, Suwon 16229, Republic of Korea.
LA  - eng
PT  - Journal Article
PT  - Observational Study
DEP - 20230601
PL  - England
TA  - J Diabetes Res
JT  - Journal of diabetes research
JID - 101605237
RN  - WTT295HSY5 (dulaglutide)
SB  - IM
MH  - Humans
MH  - *Diabetes Mellitus, Type 2/drug therapy
MH  - Retrospective Studies
MH  - Risk Factors
MH  - *Hypertension
PMC - PMC10250096
COIS- The authors declare that they have no conflicts of interest.
EDAT- 2023/06/12 06:42
MHDA- 2023/06/13 06:42
PMCR- 2023/06/01
CRDT- 2023/06/12 04:23
PHST- 2023/01/03 00:00 [received]
PHST- 2023/04/26 00:00 [revised]
PHST- 2023/05/16 00:00 [accepted]
PHST- 2023/06/13 06:42 [medline]
PHST- 2023/06/12 06:42 [pubmed]
PHST- 2023/06/12 04:23 [entrez]
PHST- 2023/06/01 00:00 [pmc-release]
AID - 10.1155/2023/7917641 [doi]
PST - epublish
SO  - J Diabetes Res. 2023 Jun 1;2023:7917641. doi: 10.1155/2023/7917641. eCollection 
      2023.